Scarica l'app Stockscreener
62.58
0.55%
0.30
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTCT Giù?
Forum
Previsione
Precedente Chiudi:
$62.28
Aprire:
$62.65
Volume 24 ore:
362.04K
Relative Volume:
0.26
Capitalizzazione di mercato:
$5.22B
Reddito:
$1.73B
Utile/perdita netta:
$682.64M
Rapporto P/E:
8.089
EPS:
7.7364
Flusso di cassa netto:
$411.18M
1 W Prestazione:
-4.20%
1M Prestazione:
-14.76%
6M Prestazione:
-6.18%
1 anno Prestazione:
+8.27%
Intervallo 1D:
$61.66
$63.13
Intervallo di 1 settimana:
$61.23
$66.58
Portata 52W:
$57.78
$90.87
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Nome
Ptc Therapeutics Inc
Settore
Industria
Telefono
(908) 222-7000
Indirizzo
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT vs VRTX, REGN, MRNA, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
62.59 | 5.20B | 1.73B | 682.64M | 411.18M | 7.7364 |
VRTX
Vertex Pharmaceuticals Inc
|
520.59 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
786.95 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
197.51 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
961.17 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
209.76 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Iniziato | Raymond James | Outperform |
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2025-12-01 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-06-17 | Iniziato | Truist | Buy |
| 2025-05-09 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-05-07 | Aggiornamento | Citigroup | Sell → Neutral |
| 2025-03-11 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Iniziato | Scotiabank | Sector Perform |
| 2024-12-13 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-09-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-08-26 | Ripresa | UBS | Buy |
| 2024-05-20 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-10-30 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Downgrade | Citigroup | Neutral → Sell |
| 2023-10-06 | Downgrade | Truist | Buy → Hold |
| 2023-09-18 | Downgrade | Citigroup | Buy → Neutral |
| 2023-09-15 | Downgrade | Raymond James | Outperform → Underperform |
| 2023-03-17 | Iniziato | SVB Securities | Market Perform |
| 2022-12-14 | Iniziato | Goldman | Sell |
| 2022-09-12 | Iniziato | Jefferies | Buy |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2022-04-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-03-29 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-11-30 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-10-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-04-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-02-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-05-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Iniziato | Bernstein | Outperform |
| 2018-10-03 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-06-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Downgrade | JP Morgan | Neutral → Underweight |
Mostra tutto
Ptc Therapeutics Inc Borsa (PTCT) Ultime notizie
PTC Therapeutics stock gets a Fabry therapy catalyst - AD HOC NEWS
PTC Therapeutics, Inc. (PTCT) Stock Forecasts - Yahoo Finance
PTC Therapeutics stock rises as third quarter data strengthen outlook - AD HOC NEWS
(PTCT) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
PTC Therapeutics, Inc. (PTCT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cantor raises PTC Therapeutics stock price target on Fabry deal By Investing.com - Investing.com Canada
Cantor Fitzgerald Boosts PTC Therapeutics (NASDAQ:PTCT) Price Target to $137.00 - MarketBeat
Cantor Fitzgerald maintains Overweight rating on PTC Therapeutics, $137 price target - TradingView
PTC Therapeutics completes ST-920 gene therapy acquisition By Investing.com - Investing.com Nigeria
PTC Therapeutics completes ST-920 gene therapy acquisition - Investing.com
PTC Therapeutics Closes Acquisition of the ST-920 Gene Therapy for Fabry Disease - Yahoo Finance
PTC Completes Acquisition of ST-920, BLA Submission Expected in Q4 2026 - TradingView
A one-time gene therapy for Fabry disease is now PTC’s. FDA filing expected later in 2026. - Stock Titan
PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy - Yahoo Finance
PTC Therapeutics (PTCT) Could Be 36% Undervalued Following Pipeline Progress - Yahoo Finance
Bank of America Corp DE Takes $118.46 Million Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics director Schmertzler sells $1.35m shares - Investing.com
Wall Street Zen Upgrades PTC Therapeutics (NASDAQ:PTCT) to "Strong-Buy" - MarketBeat
PTC Therapeutics director Schmertzler sells $1.35m shares By Investing.com - Investing.com Nigeria
PTC Therapeutics (NASDAQ:PTCT) Director Sells 10,000 Shares - MarketBeat
PTC Therapeutics Director Michael Schmertzler Executes 20,000 Share Sale Under 10b5-1 Trading Plan - Kalkine Media
PTC Therapeutics (NASDAQ: PTCT) director offloads 20,000 shares under trading plan - Stock Titan
Is PTC Therapeutics (PTCT) Undervalued After Its Recent Pullback? - simplywall.st
ETFs Investing in PTC Therapeutics, Inc. Stocks - TradingView
PTC Therapeutics at Morgan Stanley conference: sephience drives outlook By Investing.com - Investing.com Nigeria
PTC Therapeutics, Inc. $PTCT Shares Sold by Engineers Gate Manager LP - MarketBeat
California State Teachers Retirement System Lowers Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Leerink Partners Begins Coverage on PTC Therapeutics (NASDAQ:PTCT) - MarketBeat
(PTCT) Volatility Zones as Tactical Triggers - Stock Traders Daily
PTC Therapeutics director Schmertzler sells $1.35m in stock - investing.com
PTC Therapeutics director Schmertzler sells $1.35m in stock By Investing.com - Investing.com India
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Director Sells 10,000 Shares of Stock - MarketBeat
Director stock sale at PTC Therapeutics (PTCT) ran on a preset 10b5-1 plan - Stock Titan
PTC Therapeutics at cantor healthcare conference: sephience drives growth By Investing.com - Investing.com Canada
VIRGINIA RETIREMENT SYSTEMS ET Al Invests $2.32 Million in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics at Wells Fargo conference: sufiance drives growth plan By Investing.com - Investing.com Canada
Hsbc Holdings PLC Reduces Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
Corient Private Wealth LP Makes New Investment in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last? - Eastern Progress
Wells Fargo Sticks to Its Buy Rating for PTC Therapeutics (PTCT) - theglobeandmail.com
Wells Fargo Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $109 - Moomoo
Moore Capital Management LP Acquires 30,894 Shares of PTC Therapeutics, Inc. $PTCT - MarketBeat
Wellington Management Group LLP Raises Stake in PTC Therapeutics, Inc. $PTCT - MarketBeat
Empowered Funds LLC Acquires Shares of 81,271 PTC Therapeutics, Inc. $PTCT - MarketBeat
Legal & General Group Plc Makes New Investment in PTC Therapeutics, Inc. $PTCT - MarketBeat
Palo Alto Investors LP Invests $74.95 Million in PTC Therapeutics, Inc. $PTCT - MarketBeat
Hsbc Holdings PLC Takes $10.76 Million Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc.: Upfront Payment of $111 Million, Plus Up to an Additional $100 Million in Contingent Milestone Payments >PTCT - Moomoo
PTC Therapeutics director Michael Schmertzler sells $1.8m in shares - Investing.com
Michael Schmertzler Sells 12,500 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
Ptc Therapeutics Inc Azioni (PTCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ptc Therapeutics Inc Azioni (PTCT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| SCHMERTZLER MICHAEL | Director |
Sep 16 '26 |
Sale |
67.12 |
10,000 |
671,195 |
1,306,594 |
| SCHMERTZLER MICHAEL | Director |
Sep 09 '26 |
Sale |
67.84 |
10,000 |
678,403 |
1,326,594 |
| SCHMERTZLER MICHAEL | Director |
Sep 10 '26 |
Sale |
67.34 |
10,000 |
673,400 |
1,316,594 |
4.12%
1.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):